1. Market Research
  2. > B-Cell Lymphomas - Pipeline Review, H2 2013

B-Cell Lymphomas - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 121 pages

B-Cell Lymphomas - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'B-Cell Lymphomas - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Lymphomas. B-Cell Lymphomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Lymphomas.
- A review of the B-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the B-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for B-Cell Lymphomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding B-Cell Lymphomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

B-Cell Lymphomas - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
B-Cell Lymphomas Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for B-Cell Lymphomas 11
B-Cell Lymphomas Therapeutics under Development by Companies 13
B-Cell Lymphomas Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
B-Cell Lymphomas Therapeutics - Products under Development by Companies 21
B-Cell Lymphomas Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in B-Cell Lymphomas Therapeutics Development 23
Biogen Idec Inc. 23
Amgen Inc. 24
MedImmune LLC 25
Lentigen Corporation 26
Infinity Pharmaceuticals, Inc. 27
Millennium Pharmaceuticals, Inc. 28
Astellas Pharma Inc. 29
Eisai Co., Ltd. 30
Glenmark Pharmaceuticals Ltd. 31
Celgene Corporation 32
Merck KGaA 33
IMMUNOMEDICS, INC 34
Idera Pharmaceuticals, Inc. 35
Accentia Biopharmaceuticals, Inc. 36
Pharmacyclics, Inc. 37
Abiogen Pharma S.p.A. 38
Celentyx Ltd. 39
Semafore Pharmaceuticals, Inc. 40
Immune System Therapeutics Ltd. 41
Mirna Therapeutics, Inc. 42
Dynamix Pharmaceuticals Ltd. 43
LFB Biotechnologies, S.A.S.U. 44
Neopharm Ltd. 45
B-Cell Lymphomas - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
dasiprotimut T - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
MDX-1458 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
SF-1126 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
FBTA-05 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
IMO-4200 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
MEDI-551 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
DI-B4 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Combotox - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Photochemically Inactivated EBV Infected B Cell Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
DNA Vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Kappa CD28 T Cells - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
MRX-34 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
rituximab - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
ocaratuzumab - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
CC-292 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
duvelisib - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
ASP-3026 - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
GBR-401 - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
Leukothera - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
DNX-4000 - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
rituximab biosimilar - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
Anti-CD19-CAR-Transduced T Cells - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
rituximab biosimilar - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
131I-Rituximab - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
Novotarg - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
IGN-002 - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
LG-740 - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
KN-001 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
Drug Targeting EZH2-EED - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
MKC-4659 - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
hA19 Antibody - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
FX-11 - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
B-Cell Lymphomas Therapeutics - Drug Profile Updates 95
B-Cell Lymphomas Therapeutics - Discontinued Products 111
B-Cell Lymphomas Therapeutics - Dormant Products 112
B-Cell Lymphomas - Product Development Milestones 113
Featured News and Press Releases 113
Sep 09, 2013: TG Therapeutics' Ublituximab Receives Orphan Drug Designation for the Treatment of Nodal Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma 113
Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio 113
Jun 19, 2013: Senesco Announces Results Of Cohort 2 Of Its SNS01-T Phase Ib/IIa Trial 114
Jun 17, 2013: TG Therapeutics Presents Clinical Poster Presentations On TG-1101 At EHA Meeting 115
Jun 03, 2013: MethylGene Presents Clinical Data On Mocetinostat At ASCO 2013 Annual Meeting 115
May 28, 2013: MethylGene To Present Mocetinostat Data At 2013 ASCO Annual Meeting 116
May 16, 2013: TG Therapeutics To Present Phase I Study Data Of Ublituximab At ASCO Annual Meeting 116
May 15, 2013: Infinity Pharma Announces Presentation Of Clinical Data On IPI-145 At ASCO 2013 And 12th International Conference On Malignant Lymphoma 117
Apr 10, 2013: Immunomedics Presents Data On Mechanism Of Action Of Epratuzumab At AACR Annual Meeting 2013 118
Mar 28, 2013: Actinobac Biomed Receives $202,000 From National Institutes of Health To Advance Blood Cancer Research 118
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 120
Contact Us 121
Disclaimer 121



List of Tables

Number of Products Under Development for B-Cell Lymphomas, H2 2013 11
Products under Development for B-Cell Lymphomas - Comparative Analysis, H2 2013 12
Number of Products under Development by Companies, H2 2013 14
Number of Products under Development by Companies, H2 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2013 16
Comparative Analysis by Late Stage Development, H2 2013 17
Comparative Analysis by Mid Clinical Stage Development, H2 2013 18
Comparative Analysis by Early Clinical Stage Development, H2 2013 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 20
Products under Development by Companies, H2 2013 21
Products under Investigation by Universities/Institutes, H2 2013 22
Biogen Idec Inc., H2 2013 23
Amgen Inc., H2 2013 24
MedImmune LLC, H2 2013 25
Lentigen Corporation, H2 2013 26
Infinity Pharmaceuticals, Inc., H2 2013 27
Millennium Pharmaceuticals, Inc., H2 2013 28
Astellas Pharma Inc., H2 2013 29
Eisai Co., Ltd., H2 2013 30
Glenmark Pharmaceuticals Ltd., H2 2013 31
Celgene Corporation, H2 2013 32
Merck KGaA, H2 2013 33
IMMUNOMEDICS, INC, H2 2013 34
Idera Pharmaceuticals, Inc., H2 2013 35
Accentia Biopharmaceuticals, Inc., H2 2013 36
Pharmacyclics, Inc., H2 2013 37
Abiogen Pharma S.p.A., H2 2013 38
Celentyx Ltd., H2 2013 39
Semafore Pharmaceuticals, Inc., H2 2013 40
Immune System Therapeutics Ltd., H2 2013 41
Mirna Therapeutics, Inc., H2 2013 42
Dynamix Pharmaceuticals Ltd., H2 2013 43
LFB Biotechnologies, S.A.S.U., H2 2013 44
Neopharm Ltd., H2 2013 45
Assessment by Monotherapy Products, H2 2013 46
Assessment by Stage and Route of Administration, H2 2013 48
Assessment by Stage and Molecule Type, H2 2013 51
B-Cell Lymphomas Therapeutics - Drug Profile Updates 95
B-Cell Lymphomas Therapeutics - Discontinued Products 111
B-Cell Lymphomas Therapeutics - Dormant Products 112



List of Figures

Number of Products under Development for B-Cell Lymphomas, H2 2013 11
Products under Development for B-Cell Lymphomas - Comparative Analysis, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 16
Late Stage Products, H2 2013 17
Mid Clinical Stage Products, H2 2013 18
Early Clinical Stage Products, H2 2013 19
Discovery and Pre-Clinical Stage Products, H2 2013 20
Assessment by Monotherapy Products, H2 2013 46
Assessment by Route of Administration, H2 2013 47
Assessment by Stage and Route of Administration, H2 2013 48
Assessment by Molecule Type, H2 2013 49
Assessment by Stage and Molecule Type, H2 2013 50



Companies Mentioned

Biogen Idec Inc.
Amgen Inc.
MedImmune LLC
Lentigen Corporation
Infinity Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Astellas Pharma Inc.
Eisai Co., Ltd.
Glenmark Pharmaceuticals Ltd.
Celgene Corporation
Merck KGaA
IMMUNOMEDICS, INC
Idera Pharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc.
Pharmacyclics, Inc.
Abiogen Pharma S.p.A.
Celentyx Ltd.
Semafore Pharmaceuticals, Inc.
Immune System Therapeutics Ltd.
Mirna Therapeutics, Inc.
Dynamix Pharmaceuticals Ltd.
LFB Biotechnologies, S.A.S.U.
Neopharm Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.